Ribonucleoside analogue
Treatment of infections caused by RNA viral pathogens, including SARS-CoV-2
Target
SARS coronavirus replicase [KO:K24149]
Pathway
ko03230
Viral genome structure
ko05171
Coronavirus disease - COVID-19
Brite
Drug groups [BR:br08330]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D11943 Molnupiravir
Drug classes [BR:br08332]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D11943 Molnupiravir
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
Other inhibitor
D11943 Molnupiravir (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11943
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11943
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11943
Other DBs
CAS:
2492423-29-5
ChEBI:
180653
KCF data
ATOM 23
1 C8x C 17.8926 -17.2912
2 N4y N 17.8926 -18.6989
3 C8y C 19.0892 -19.4028
4 N4x N 20.3562 -18.6989
5 C8y C 20.3562 -17.2912
6 C8x C 19.0892 -16.5873
7 C1y C 16.6960 -19.4028
8 O2x O 15.4995 -18.6286
9 C1y C 14.4437 -19.4732
10 C1y C 14.8660 -20.7402
11 C1y C 16.2737 -20.7402
12 C1b C 13.2471 -18.7693
13 O7a O 12.0505 -19.4732
14 C7a C 10.8539 -18.7693
15 C1c C 9.6573 -19.4732
16 C1a C 8.4608 -18.7693
17 C1a C 9.6573 -20.8809
18 O6a O 10.8539 -17.3616
19 N2b N 21.5527 -16.5873
20 O1b O 22.8197 -17.2912
21 O1a O 14.0213 -21.8664
22 O1a O 17.1184 -21.8664
23 O5x O 19.1423 -20.7895
BOND 24
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 7 2 1 #Up
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 7 11 1
13 9 12 1 #Up
14 12 13 1
15 13 14 1
16 14 15 1
17 15 16 1
18 15 17 1
19 14 18 2
20 5 19 2
21 19 20 1
22 10 21 1 #Down
23 11 22 1 #Down
24 3 23 2